Method Profile

Drug Protection Against Cholesterol Stress in Forebrain Organoids

Survival, lipid, mitochondrial, expression and calcium-imaging readouts compare semaglutide responses in forebrain organoids at different maturation stages.

Brain & Neural ModelsOrganoids
No.2 Teaching Building at Tsinghua University in Beijing.
Tsinghua University’s No.2 Teaching Building in Beijing, photographed in 2024. (HoweyYuan, CC BY-SA 4.0)

Research Applications

Mechanistic and functional comparison of drug responses under neural metabolic stress.

Model & Design

Forebrain organoids derived from DXR0109B and DYR0100 hiPSC lines, with complementary two-dimensional neural progenitor cell assays.

Experimental Format

Early and day-65-to-80 exposure windows; 100 nM semaglutide, 10 μg/mL cholesterol and corresponding unstressed, stressed and vehicle controls.

Model Components

  • Component

    Human forebrain models

    Description

    hiPSC-derived forebrain organoids and neural progenitor cells; the organoids lack microglia, functional vasculature, aging-related features and Alzheimer’s-associated genetic backgrounds.

  • Component

    Pharmacological comparisons

    Description

    The GLP-1 receptor antagonist C5d and PKA/PI3K inhibitors probe receptor dependence and signaling contributions.

  • Component

    Functional and molecular readouts

    Description

    Live/dead imaging, neural progenitor cell CCK-8 assays, lipid droplets, reactive oxygen species, protein and RNA measurements, and Fluo-4 AM calcium imaging analyzed with Fiji and Python.

Measurements & Endpoints

  • Viability and apoptosis
  • Size and tissue structure
  • Lipid droplets and reactive oxygen species
  • Pathway expression and phosphorylation
  • Calcium event frequency and synchrony
  • APP and p-tau217

Analysis

Compare treatment and pharmacological blockade within each maturation stage. Interpret transcript-based cell–cell communication as an inference and Fluo-4 signals as cellular calcium activity.

Published Evidence

  • Study Design

    Cholesterol stress with semaglutide co-treatment, receptor blockade and separate early- and later-stage assessments.

    Study Sample

    Early Figure 2 size measurements used 13 organoids per group, viability assays six independent experiments and protein measurements four. Sample sizes differ by endpoint.

    Comparison

    Unstressed controls, cholesterol alone, cholesterol with semaglutide, and pharmacological blockade conditions.

    Finding

    Early survival, size and apoptosis measures improved. At day 80, overall area and APP/p-tau217 did not significantly recover; calcium event frequency improved while synchrony recovery was limited.

    Interpretation & Limits
    • This is a cholesterol-stress model with limited disease specificity, not a complete model of Alzheimer’s disease.
    • Inferred cell–cell signaling requires functional testing. Exposure in the human brain cannot be inferred directly from the in vitro concentrations.

Sources

  1. GLP‐1R agonist semaglutide protects human forebrain organoids from cholesterol‐induced neurotoxicity. Alzheimer's & Dementia (2026). ↗